Drugs / GSK4382276A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05446740 | Aug 2022 → Mar 2024 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4382276A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05446740 ↗ |
| Modality | Messenger RNA (mRNA) | “investigational mRNA-based monovalent influenza vaccine” PMID 41701031 ↗ Feb 2026 |